Announcement on Implementation of Dividend Distribution for 2025
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Implementation of Dividend Distribution for 2025
Filed with SSE · · 4 pages · Chinese
Release
Gan & Lee Pharmaceuticals Co., Ltd. on 6ix
Earlier from Gan & Lee Pharmaceuticals
- Announcement on Obtaining of European Commission Marketing Authorization for Insulin Lispro Injection
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Obtaining of European Commission Marketing Authorization for Aspart Injection
- Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of New Indication of Bofanglutide (GZR18) Injection
- Notice on Convening the 2025 Annual General Meeting
Later from Gan & Lee Pharmaceuticals
- Announcement on Sterile Preparations Passing ANVISA GMP Certification
- Announcement on Release of Pledge of Partial Shares Held by Shareholders with Over 5% Shares
- Notice on Convening the 1st Extraordinary General Meeting in 2026
- Indicative Announcement on Unlocking of the 3rd Sales Restriction Lifting Period under the 2022 Restricted Stock Incentive Plan and Unlocking and Listing of the 2nd Sales Restriction Lifting Period under the 2024 Restricted Stock Incentive Plan
- Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
Follow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.
Follow Gan & Lee Pharmaceuticals